Oncopeptides AB (publ) (ONPPF)
USD 0.27
(-70.56%)
USD 0.27
(-70.56%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 181.59 Million SEK | 99.49% |
| 2022 | 91.03 Million SEK | -60.16% |
| 2021 | 228.5 Million SEK | -38.22% |
| 2020 | 369.85 Million SEK | 88.25% |
| 2019 | 196.47 Million SEK | 52.66% |
| 2018 | 128.69 Million SEK | 108.19% |
| 2017 | 61.81 Million SEK | 111.01% |
| 2016 | 29.29 Million SEK | 318.39% |
| 2015 | 7 Million SEK | 26.91% |
| 2014 | 5.51 Million SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 208.11 Million SEK | 14.6% |
| 2024 Q2 | 259.95 Million SEK | 24.91% |
| 2023 Q1 | 88.46 Million SEK | -2.82% |
| 2023 Q2 | 178.86 Million SEK | 102.2% |
| 2023 FY | 181.59 Million SEK | 99.49% |
| 2023 Q3 | 161.58 Million SEK | -9.67% |
| 2023 Q4 | 181.59 Million SEK | 12.39% |
| 2022 Q2 | 90.8 Million SEK | -36.03% |
| 2022 Q3 | 95.74 Million SEK | 5.44% |
| 2022 Q4 | 91.03 Million SEK | -4.92% |
| 2022 FY | 91.03 Million SEK | -60.16% |
| 2022 Q1 | 141.93 Million SEK | -37.88% |
| 2021 Q1 | 354.67 Million SEK | -4.11% |
| 2021 Q2 | 263.75 Million SEK | -25.63% |
| 2021 Q3 | 215.38 Million SEK | -18.34% |
| 2021 Q4 | 228.5 Million SEK | 6.09% |
| 2021 FY | 228.5 Million SEK | -38.22% |
| 2020 Q2 | 272.12 Million SEK | 69.79% |
| 2020 Q1 | 160.27 Million SEK | -18.43% |
| 2020 FY | 369.85 Million SEK | 88.25% |
| 2020 Q4 | 369.85 Million SEK | 47.83% |
| 2020 Q3 | 250.19 Million SEK | -8.06% |
| 2019 Q2 | 216.18 Million SEK | 70.9% |
| 2019 FY | 196.47 Million SEK | 52.66% |
| 2019 Q1 | 126.49 Million SEK | -1.71% |
| 2019 Q3 | 150.75 Million SEK | -30.26% |
| 2019 Q4 | 196.47 Million SEK | 30.33% |
| 2018 Q2 | 132.17 Million SEK | 51.92% |
| 2018 Q4 | 128.69 Million SEK | -2.48% |
| 2018 FY | 128.69 Million SEK | 108.19% |
| 2018 Q1 | 87 Million SEK | 40.75% |
| 2018 Q3 | 131.96 Million SEK | -0.16% |
| 2017 Q3 | 50.59 Million SEK | -19.12% |
| 2017 Q2 | 62.56 Million SEK | 32.46% |
| 2017 Q4 | 61.81 Million SEK | 22.17% |
| 2017 Q1 | 47.23 Million SEK | 61.23% |
| 2017 FY | 61.81 Million SEK | 111.01% |
| 2016 Q4 | 29.29 Million SEK | 0.0% |
| 2016 Q1 | - SEK | 0.0% |
| 2016 FY | 29.29 Million SEK | 318.39% |
| 2015 FY | 7 Million SEK | 26.91% |
| 2014 FY | 5.51 Million SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Capstone Therapeutics Corp. | 50.26 Million USD | -261.288% |
| Skye Bioscience, Inc. | 14.07 Million USD | -1190.471% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | -207.72% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -22352.936% |
| Qrons Inc. | 1.48 Million USD | -12098.322% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -406195.865% |
| Adynxx, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | 9.46 Million USD | -1818.44% |
| BioStem Technologies, Inc. | 15.9 Million USD | -1041.791% |
| Regen BioPharma, Inc. | 5.45 Million USD | -3227.424% |
| CSL Limited | 18.62 Billion USD | 99.025% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | -142.389% |
| Evofem Biosciences, Inc. | 72.47 Million USD | -150.58% |
| Rebus Holdings, Inc. | 5.24 Million USD | -3364.288% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -661869.161% |
| Neon Bloom, Inc. | 1.22 Million USD | -14709.662% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -90195.153% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | -240.677% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | -1795.195% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -42976.799% |
| SQZ Biotechnologies Company | 50.03 Million USD | -262.913% |
| Intellipharmaceutics International Inc. | 12 Million USD | -1412.212% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -4615.087% |
| Mesoblast Limited | 188.44 Million USD | 3.633% |
| Marizyme, Inc. | 26.67 Million USD | -580.762% |
| Genus plc | 485 Million USD | 62.557% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -3008.16% |
| Pharming Group N.V. | 244.07 Million USD | 25.597% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -8934.142% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -7116.786% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -4678.895% |
| ContraFect Corporation | 32.53 Million USD | -458.231% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -9065.561% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -4644.376% |
| IMV Inc. | 37.93 Million USD | -378.736% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | -1441.815% |
| MultiCell Technologies, Inc. | 1617.67 USD | -11225798.978% |
| ONE Bio Corp. | 27.49 Million USD | -560.457% |
| Accustem Sciences Inc. | 1.07 Million USD | -16726.486% |
| RVL Pharmaceuticals plc | 77.41 Million USD | -134.571% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | -8485.914% |
| Q BioMed Inc. | 8.13 Million USD | -2132.871% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | -118.964% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -3428.892% |
| Biomind Labs Inc. | 1.49 Million USD | -12017.746% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | -52.96% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | -1908.34% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | -886.763% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -12564.965% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -127700.415% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -3060.523% |
| GB Sciences, Inc. | 5.41 Million USD | -3252.027% |
| Alpha Cognition Inc. | 7.16 Million USD | -2434.595% |
| HST Global, Inc. | 593.59 Thousand USD | -30493.016% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -14321.776% |
| Halberd Corporation | 728.71 Thousand USD | -24820.168% |
| Enzolytics Inc. | 365.26 Million USD | 50.284% |
| Agentix Corp. | 2.51 Million USD | -7133.381% |
| Resverlogix Corp. | 67.39 Million USD | -169.449% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -21551.493% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 59.187% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -10494.982% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | -633.847% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | -1425.636% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -4854.703% |
| AVAX Technologies, Inc. | 3.99 Million USD | -4447.06% |
| Zenith Capital Corp. | 27.56 Thousand USD | -658603.616% |
| Genscript Biotech Corporation | 1.32 Billion USD | 86.304% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -75992.586% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -4762.965% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -26572.875% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -6596.978% |
| Kadimastem Ltd | 3.5 Million USD | -5081.309% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -271229.319% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -38978.629% |
| LadRx Corporation | 2.2 Million USD | -8152.474% |
| Cell Source, Inc. | 15.8 Million USD | -1048.866% |
| Regen BioPharma, Inc. | 5.45 Million USD | -3227.424% |
| NovAccess Global Inc. | 7.86 Million USD | -2210.192% |
| Affymax, Inc. | 8.87 Million USD | -1947.097% |
| Itoco Inc. | 1.65 Million USD | -10884.961% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -8751.682% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -2902.116% |
| Mobile Lads Corp. | 1.31 Million USD | -13725.536% |
| CytoDyn Inc. | 127.89 Million USD | -41.991% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -434355.37% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -11493.505% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | -1544.122% |
| SYBLEU INC | 681.41 Thousand USD | -26550.211% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -2876.087% |
| International Stem Cell Corporation | 5.27 Million USD | -3341.311% |
| Bioxytran, Inc. | 3.24 Million USD | -5488.491% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -28918.119% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -3833.14% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | -342.965% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | -715.621% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -8866.089% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -3215.042% |
| Neutra Corp. | 973.52 Thousand USD | -18553.579% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | -525.876% |
| PureTech Health plc | 125.58 Million USD | -44.604% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -4733.43% |
| IXICO plc | 1.9 Million USD | -9456.321% |
| IntelGenx Technologies Corp. | 20.52 Million USD | -784.593% |
| Gelesis Holdings, Inc. | 103.32 Million USD | -75.756% |
| CSL Limited | 18.62 Billion USD | 99.025% |
| Cellectis S.A. | 249.36 Million USD | 27.177% |